Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Gemzar Clear all

Conditions: Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasm
Interventions: KHK2866, Gemcitabine and Carboplatin, paclitaxel, pegylated liposomal doxorubicin; Biological · Drug
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Tucson, Arizona • Los Angeles, California • Boston, Massachusetts + 2 more

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine; Drug
Lead sponsor: Pancreatic Cancer Action Network; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Non-small Cell Lung Cancer
Interventions: Filgrastim-SD/01; Drug
Lead sponsor: Schwartzberg, Lee, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 2
States / cities: Southaven, Mississippi • Memphis, Tennessee

Conditions: Malignant Pleural Mesothelioma
Interventions: rAd-IFN, Celecoxib Oral Product, Gemcitabine; Biological · Drug
Lead sponsor: Ferring Ventures Limited; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Tampa, Florida + 3 more

Conditions: Neoplasms
Interventions: Perifosine, Gemcitabine; Drug
Lead sponsor: AEterna Zentaris; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Johnson City, Tennessee

Conditions: Sarcoma
Interventions: Docetaxel, Gemcitabine, Vorinostat, Pegfilgrastim; Drug
Lead sponsor: Melissa Burgess, MD; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hodgkin Disease
Interventions: Doxorubicin, Vinblastine, Cyclophosphamide, Etoposide, Vincristine, Bleomycin, Gemcitabine, Vinorelbine, Prednisone; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Stanford, California

Conditions: Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Gemcitabine, Nab-paclitaxel, L-glutamine; Drug
Lead sponsor: Jun Gong, MD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Beverly Hills, California • Los Angeles, California

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Avelumab, Utomilumab, Rituximab, Azacitidine, Bendamustine, Gemcitabine, Oxaliplatin; Biological · Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Duarte, California • Louisville, Kentucky • New Orleans, Louisiana + 4 more

Conditions: Colorectal Cancer, Colon Cancer
Interventions: gemcitabine, capecitabine; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Interventions: Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 18
States / cities: Tucson, Arizona • Encinitas, California • La Jolla, California + 15 more

Conditions: Pancreatic Neoplasms
Interventions: Gemcitabine, AG-013736; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 17
States / cities: Antioch, California • Berkeley, California • Concord, California + 11 more

Conditions: Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7
Interventions: Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nab-paclitaxel, Paricalcitol, Pembrolizumab, Therapeutic Conventional Surgery; Drug · Other · Biological + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Neoplasms, Pancreatic Neoplasms
Interventions: nab-Paclitaxel, Nivolumab, Gemcitabine, Carboplatin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 15
States / cities: Sacramento, California • Santa Monica, California • New Haven, Connecticut + 11 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: capecitabine, gemcitabine hydrochloride, imatinib mesylate, mutation analysis, nucleic acid sequencing, polymerase chain reaction; Drug · Genetic
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Advanced Cancer, Breast Cancer, Sarcoma, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian
Interventions: Pembrolizumab, Gemcitabine, Docetaxel, Nab-paclitaxel, Vinorelbine, Irinotecan, Liposomal Doxorubicin; Drug
Lead sponsor: Western Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Goodyear, Arizona

Conditions: Soft Tissue Sarcoma
Interventions: ADI PEG20, Placebo; Drug · Other
Lead sponsor: Polaris Group; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 21 more

Conditions: Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma) (ICC)
Interventions: Liver resection and placement of hepatic artery infusion pump, FLOXURIDINE, DEXAMETHASONE, GEMCITABINE; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: erlotinib hydrochloride, gemcitabine hydrochloride; Drug
Lead sponsor: OSI Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 2
States / cities: Tucson, Arizona • San Antonio, Texas

Conditions: Urothelial Cancer, Urinary Bladder Neoplasms
Interventions: Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy, Cisplatin, Fluorouracil, Mitomycin C, Gemcitabine, Pembrolizumab; Drug · Radiation
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 21
States / cities: Little Rock, Arkansas • Santa Barbara, California • Aurora, Colorado + 18 more

Conditions: Stage IV Non-Small Cell Lung Cancer
Interventions: Stereotactic Body Radiation Therapy, Maintenance chemotherapy; Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lung Cancer
Interventions: gemcitabine hydrochloride, pemetrexed disodium; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 22
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more

Conditions: Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer
Interventions: fluorouracil, gemcitabine hydrochloride, triacetyluridine; Drug
Lead sponsor: Wellstat Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 26
States / cities: Birmingham, Alabama • Burbank, California • Duarte, California + 22 more

Conditions: Bladder Cancer
Interventions: Pembrolizumab, Enfortumab vedotin (EV), RC + PLND, Gemcitabine, Cisplatin; Biological · Procedure · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 22
States / cities: Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more

Search by objective public record fields.

Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients

Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

Phase I Perifosine and Gemcitabine Study

Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma

Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease

Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma

Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial

Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)